Given the role of IgA in mucosal immunity (Chao et al., 2020) and the reports on the association of IgA with the criticality of COVID-19 disease (Zervou et al., 2021), it appears that CP patients are indeed vulnerable to secondary bacterial infections. The gene discussed is CD79A; the disease is bacterial infectious disease.